Replies to post #71115 on Biotech Values

[DewDiligence]

Just wondering how you now see Anadys as an investment, in light of today's clinical data? Their 2008 year end cash level is in the $25-27 mil range (as per today's conf call)…

I think ANDS will try to raise money in the near future and that’s why they rushed to issue a half-baked PR.

Note that ANDS had originally planned to release the results from the first three cohorts of the phase-1b study at the same time (#msg-34659553). You don’t have to be a genius to surmise the reason why they opted instead to make a splash with data from only one cohort: they think the funding window might have reopened a crack and it may not stay open for long.

Bottom line: if you’re interested in owning this stock, don’t chase it; instead, wait for the financing deal. JMHO. FWIW